AKT1 and cancer: Especially, they significantly decreased VEGFA, phosphorylated erythroblastic oncogene B-2 gene (p-ERBB2), p-AKT and p-VEGFR at the dose of 300 and 400 μg/mL, suggesting that anti-cancer effects were improved with increased dosages [70].